Lista de obras -

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid

artículo científico publicado en 2016

A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations

artículo científico publicado en 2017

APP-derived peptides reflect neurodegeneration in frontotemporal dementia

artículo científico publicado en 2019

Accelerating drug development for Alzheimer's disease through the use of data standards

artículo científico publicado en 2017

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

artículo científico publicado en 2009

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

artículo científico publicado en 2015

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment

artículo científico publicado en 2005

Analytical aspects of molecular Alzheimer's disease biomarkers

artículo científico publicado en 2012

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

artículo científico publicado en 2006

Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study

artículo científico publicado en 2018

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

article

Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays

artículo científico publicado en 2018

Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

artículo científico publicado en 2016

C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction With Magnetic Resonance Imaging Markers

artículo científico publicado en 2018

CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation

artículo científico publicado en 2016

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

artículo científico publicado en 2016

CSF biomarker variability in the Alzheimer's Association quality control program

artículo científico publicado en 2013

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease

artículo científico publicado en 2020

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

artículo científico publicado en 2017

Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy

scientific article published on 22 August 2018

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

artículo científico publicado en 2009

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

artículo científico publicado en 2014

Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis.

artículo científico publicado en 2012

Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults

artículo científico publicado en 2019

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

scientific article published on 01 January 2003

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

artículo científico publicado en 2013

Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology: How specific are the conformation-specif

scientific article published on 21 September 2020

Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements

scientific article published on 01 November 2018

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology

artículo científico publicado en 2011

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia

artículo científico publicado en 2013

Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms

artículo científico publicado en 2017

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

artículo científico publicado en 2010

Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease

artículo científico publicado en 2016

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.

artículo científico publicado en 2007

Differences and Similarities between Two Frequently Used Assays for Amyloid 42 in Cerebrospinal Fluid

article

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia

artículo científico publicado en 2017

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays

scientific article published on 17 January 2020

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

artículo científico publicado en 2004

Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

artículo científico publicado en 2008

Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway

artículo científico publicado en 2017

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

artículo científico publicado en 2011

First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays

artículo científico publicado en 2020

How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio

artículo científico publicado en 2017

Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients

artículo científico publicado en 2012

Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients

artículo científico publicado en 2007

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

artículo científico publicado en 2007

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

artículo científico publicado en 2004

Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study

artículo científico publicado en 2017

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.

artículo científico publicado en 2007

Neurofilament ELISA validation.

artículo científico publicado en 2009

Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia

artículo científico publicado en 2004

No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF.

artículo científico publicado en 2016

Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine

artículo científico publicado en 2016

Plasma Amyloid-β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study

artículo científico publicado en 2017

Plasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease.

artículo científico publicado en 2018

Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study.

artículo científico publicado en 2018

Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins

artículo científico publicado en 2004

Potential sources of interference on Abeta immunoassays in biological samples

artículo científico publicado en 2012

Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition

artículo científico publicado en 2016

Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs

artículo científico publicado en 2016

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

artículo científico publicado en 2011

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)

artículo científico publicado en 2017

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

artículo científico

Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition

artículo científico publicado en 2017

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale.

artículo científico publicado en 2018

Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes

artículo científico publicado en 2012

Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach

artículo científico

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease

artículo científico

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology

artículo científico publicado en 2004

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative

artículo científico publicado en 2011

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

scientific article published on 09 December 2019

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

artículo científico publicado en 2011

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

artículo científico publicado en 2015

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

scientific article published on 23 June 2018

Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease

artículo científico publicado en 2019

Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets

artículo científico publicado en 2003

Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.

artículo científico publicado en 2011

Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics.

artículo científico publicado en 2012

Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab

artículo científico publicado en 2013

Lista de obras de

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid

A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations

APP-derived peptides reflect neurodegeneration in frontotemporal dementia

Accelerating drug development for Alzheimer's disease through the use of data standards

Added diagnostic value of CSF biomarkers in differential dementia diagnosis

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment

Analytical aspects of molecular Alzheimer's disease biomarkers

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies

Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study

Assessing the commutability of reference material formats for the harmonization of amyloid-β measurements

Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays

Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

C-Reactive Protein, Plasma Amyloid-β Levels, and Their Interaction With Magnetic Resonance Imaging Markers

CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

CSF biomarker variability in the Alzheimer's Association quality control program

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team

Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Cerebrospinal fluid collection tubes: a critical issue for Alzheimer disease diagnosis.

Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology: How specific are the conformation-specif

Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements

Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia

Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia.

Differences and Similarities between Two Frequently Used Assays for Amyloid 42 in Cerebrospinal Fluid

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway

Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays

How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42/Aβ40 ratio

Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients

Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients

Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years.

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.

Neurofilament ELISA validation.

Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia

No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF.

Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine

Plasma Amyloid-β Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study

Plasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease.

Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study.

Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins

Potential sources of interference on Abeta immunoassays in biological samples

Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition

Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40)

Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.

Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale.

Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes

Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative

Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease

Unaltered plasma levels of beta-amyloid(1-40) and beta-amyloid(1-42) upon stimulation of human platelets

Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.

Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics.

Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab